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664 Am J PNonmalignant blood disorders currently affect millions of Americans, and their prevalence is
expected to grow over the next several decades. This is owing to improvements in treatment leading
to increased life expectancy of people with hereditary conditions, like sickle cell disease and
hemophilia, but also the rising occurrence of risk factors for venous thromboembolism. The lack of
adequate surveillance systems to monitor these conditions and their associated health indicators is
a signiﬁcant barrier to successfully assess, inform, and measure prevention efforts and progress
toward national health goals. CDC is strengthening surveillance activities for blood disorders by
improving and developing new methods that are tailored to best capture and monitor the
epidemiologic characteristics unique to each disorder. These activities will provide a robust
evidence base for public health action to improve the health of patients affected by or at risk for
these disorders.
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).IntroductionRanging from rare inherited conditions like hemo-philia to common acute events with strongnonhereditary triggers such as venous thrombo-
embolism (VTE), nonmalignant blood disorders comprise
a group of diverse conditions that are increasingly recog-
nized as important illnesses to be addressed by the public
health sector.1,2 These conditions currently affect millions
of Americans, and their prevalence is expected to grow
over the next several decades owing to improvements in
treatment, leading to increased life expectancy of people
with hereditary conditions like sickle cell disease (SCD)
and hemophilia and the rising occurrence of risk factors for
VTE.3–5 Given the public health impact of these disorders,
a new topic area, Blood Disorders and Blood Safety, was
created for Healthy People 2020 (HP2020), introducing 19
new objectives for reducing the burden of bleeding
disorders, hemoglobinopathies (SCD and thalassemia),
and VTE as well as improving and ensuring blood safety.6
However, the lack of adequate surveillance systems to
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open access article under the CC BY-NCsigniﬁcant barrier to successfully informing and assessing
prevention efforts as well as measuring progress toward
these objectives. Currently, there are no established
national population-based monitoring or surveillance sys-
tems for SCD, thalassemia, or VTE. Although there has
been ongoing monitoring of bleeding disorders, this system
historically has not collected information on patients who
received health care outside of federally funded hemophilia
treatment centers (HTCs) or comprehensive care centers
for patients with bleeding disorders. Monitoring has also
not tracked health indicators of emerging health challenges
such as chronic diseases like cardiovascular disease or
inhibitors (the development of antibodies to treatment
products) experienced by people with bleeding disorders.
Given the diversity in the clinical presentation, health-
care needs, and affected populations, no single surveil-
lance approach can effectively monitor all blood
disorders. Instead, the selection of an appropriate
method is strongly inﬂuenced by several factors, includ-
ing diagnosis and screening practices; the acute or
chronic nature of the condition; and the healthcare
utilization pattern, geographic distribution, and social
and cultural norms of the affected population. These
factors pose challenges but also provide strategic oppor-
tunities when choosing and implementing surveillance
methods. This paper discusses the principles, challenges,
and successes experienced in developing and redesigning
CDC-sponsored surveillance of bleeding disorders,
hemoglobinopathies, VTE, and blood safety.. on behalf of American Journal of Preventive Medicine. This is an
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Bleeding disorders impair the effectiveness of blood
clotting, leading to excessive bleeding, prolonged bleed-
ing, or both. Congenital or hereditary bleeding disorders
include hemophilia, von Willebrand disease (VWD), and
various platelet and clotting factor disorders. Hemophilia
is an absolute or functional deﬁciency of clotting factor
protein VIII (hemophilia A) or IX (hemophilia B),
components in the series of reactions creating ﬁbrin, a
major constituent of blood clots. In its severe form,
hemophilia can result in crippling joint bleeds and other
serious or life-threatening bleeds such as intracranial
hemorrhages. An X-linked condition, it is observed
primarily in males (about 1 in 5,000 births), affecting
an estimated 20,000 Americans.7,8 VWD, a deﬁciency or
dysfunction of von Willebrand protein, important for
platelet aggregation and stabilization of blood clots, is a
heterogeneous condition with bleeding phenotypes rang-
ing from asymptomatic to relatively severe. It is thought
to affect up to 1% of the U.S. population, occurring
equally in male and female patients, though women are
more likely to be symptomatic because of the hemostatic
challenges of menstruation and childbirth.9
CDC’s public health activities to address bleeding
disorders began during the 1980s after hemophilia
patients were disproportionately infected with HIV
through contaminated treatment products.10 In 1983,
CDC began supporting HIV risk reduction activities in
the national network of HTCs (funded by the Health
Resources and Services Administration), and in 1989
supported the development and analysis of the Hemo-
philia Minimal Data Set to monitor HIV risk reduction
service delivery at HTCs.11–13 From 1995 to 1999, CDC
conducted the six-state population-based Hemophilia
Surveillance System (HSS), which established the inci-
dence and prevalence of hemophilia in the U.S.14,15 Sixty-
six percent of patients identiﬁed in the HSS received at
least some care at an HTC and were found to have
reduced mortality and hospitalizations compared to
those who did not.8,13,15 This was followed by the
Universal Data Collection (UDC) project (1998–2011),
a national, HTC-based surveillance system for longitu-
dinal monitoring of the complications of bleeding dis-
orders, especially joint disease and bloodborne infections.
In 2010, CDC evaluated the scope and utility of the
UDC and convened a stakeholder meeting to identify
ongoing and emerging health indicators of importance
for those with bleeding disorders. Stakeholders identiﬁed
numerous areas of concern and interest, including
conditions of aging, inhibitors, and the healthcare
utilization and experiences of patients receiving care
outside of HTCs. Based on recommendations from these
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projects for monitoring the complications of bleeding
disorders. Longitudinal monitoring of health conditions
in patients receiving care in HTCs continues, including
the collection of blood specimens for centralized mon-
itoring for inhibitors, bloodborne pathogens, and other
conditions. As sites of clinical care seeing large numbers
of bleeding disorder patients, the HTCs are ideal for
collection of detailed and speciﬁc clinical data and
specimens.
Additionally, collection of data from people with
bleeding disorders who do not attend HTCs is being
piloted at non-HTC care centers and through a patient
survey to assess strategies for identifying and conducting
bleeding disorder surveillance among these patients as
well as to initiate a description of their health status. Data
are not expected to be representative of the entire non-
HTC population and thus are not expected to allow
direct comparison of health outcomes between patients
receiving care in and outside of federally funded HTCs or
to explain previously observed differences. However, they
are a step forward in understanding the care and health
status of non-HTC patients, which will contribute to our
knowledge of the public health burden of bleeding
disorders and the ultimate goal of improving health
outcomes for all bleeding disorder patients.
Hemoglobinopathies
The hemoglobinopathies are a group of inherited blood
disorders caused by mutations in the globin genes and
includes SCD and the thalassemias. There are an
estimated 72,000–98,000 people living with SCD in the
U.S.16; an estimate of the number of people living with
thalassemia is unavailable. In 2010, CDC partnered with
NIH and seven U.S. state health departments to pilot the
Registry and Surveillance System for Hemoglobinopa-
thies (RuSH), the ﬁrst statewide, population-based sur-
veillance system for hemoglobinopathies in the U.S. The
intent of this ﬁrst phase of RuSH was to utilize pre-
existing data sets to identify unique individuals living
with a hemoglobinopathy in each of the participating
states. The NIH’s plan for the next phase of the project is
to use the RuSH information to create a national
hemoglobinopathy registry.17
RuSH was conducted within state health departments
to leverage their public health authority or legislative
mandate to access the wide variety of data sets that were
required to implement the activities of RuSH.18 The
states received 2 years of funding, although most
continued their work beyond this time period. A novel,
three-tiered case deﬁnition was developed for the project,
based on laboratory results and ICD-9 and ICD-10 codes.
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newborn screening (NBS) records, vital statistics records
(birth and death), state Medicaid databases, state hospital
and emergency department databases, and specialty care
clinics. The project included data for a 5-year period
(2004–2008) that was extracted, de-duplicated, and
linked across all data sets.
By using multiple data sets, the RuSH project allowed
for a more comprehensive understanding of the hemo-
globinopathy populations in the seven states than was
already available. Previously, NBS results were used to
determine the incidence of SCD, but few states mandate
comprehensive NBS for the thalassemias. Also, there
were no systems that collected information on people
born prior to the implementation of NBS or those born
in other countries, which affected the validity of current
prevalence estimates. Moreover, most of the studies that
were published on healthcare utilization (e.g., hospital-
izations, emergency department visits, therapeutic
blood transfusions, transcranial Doppler screening) or
mortality used only one or two sources of data, which
meant that the results were limited in scope and not
generalizable to the overall hemoglobinopathy popula-
tion.19–21
The Registry and Surveillance System for Hemoglobi-
nopathies data will provide a clearer understanding of the
public health burden of hemoglobinopathies in the
participating states. The information will equip patients,
community members, healthcare providers, policy mak-
ers, and public health with a more accurate idea of where
individuals with a hemoglobinopathy live, what kind of
health care they receive, and the areas where improve-
ment is needed. Currently, work is being conducted with
two of the RuSH states to evaluate and validate the RuSH
activities and reﬁne the case deﬁnition and data collec-
tion methods. CDC’s ultimate goal is to implement a
reﬁned, RuSH-like program to collect hemoglobinopathy
data from all states in the U.S., subject to availability of
funding. These data will allow for a comparison among
states of the prevalence of the conditions, access to high-
quality health care throughout the life span, and
hemoglobinopathy-related health outcomes. Preliminary
analysis of the RuSH data (data not shown) indicates that
these measures vary greatly from state to state. However,
without a national surveillance system, it will not be
possible to fully understand and improve upon these
disparities.
Venous Thromboembolism
Venous thromboembolism includes both deep vein
thrombosis (DVT), a condition in which a blood clot
forms in the deep veins of the body, and pulmonaryembolism (PE), a potentially fatal condition that occurs
when a clot breaks free and enters the arteries of the
lungs. Numerous risk factors have been identiﬁed and
include advanced age, surgery, hospitalization, cancer,
immobilization, pregnancy, and hormones.3,22–24 The
actual number of people affected by VTE in the U.S. is
uncertain, but VTE incidence has been estimated at
300,000–900,000 cases annually and annual deaths from
PE are estimated at 100,000 or more.22–27 However,
many VTE experts have suggested that the current
estimates are not nationally representative and likely
understated given the complexity of documenting VTE
occurrence.27,28
Fortunately, many VTEs are preventable, and in 2008,
the Surgeon General released a “Call to Action to Prevent
Deep Vein Thrombosis and Pulmonary Embolism,”
urging a coordinated effort to reverse projected trends
and reduce the national burden of VTE.28 An important
part of prevention is conducting surveillance that can
accurately quantify the burden of VTE, identify those in
need of prevention efforts, and measure the effectiveness
of those efforts. However, surveillance of this condition is
challenging. DVT and PE can be diagnosed and managed
by healthcare providers in various specialties in both
inpatient and outpatient settings. Furthermore, PE may
be misdiagnosed and often presents as sudden death,
requiring an autopsy for conﬁrmation of diagnosis.
Therefore, to comprehensively capture VTE events, it is
essential to have a population-based surveillance system
with the capacity to collect and link data from multiple
sources.
In April 2012, CDC initiated funding of two 2-year
pilot VTE surveillance projects. Each awardee is devel-
oping and implementing population-based surveillance
to capture inpatient, outpatient, and death-related VTE
events in a speciﬁc geographic area (county). Both
projects will be evaluated to assess their ability to (1)
describe and establish population-based estimates of
VTE burden; (2) monitor and describe associated mor-
bidity and mortality; (3) monitor trends over time and
evaluate outcomes, recurrence, and the effect of preven-
tion measures; and (4) identify areas for further public
health research. Although they are each implementing
unique approaches to case ascertainment and data
collection, similar case deﬁnitions and indicators are
being used and collected to ensure consistency and
comparability between the two projects.
Capturing the entire burden of VTE in a county is
challenging because of cases in which PE presents as
sudden death and an autopsy is not performed or
instances in which county residents develop VTE and
obtain care outside of the county. Both awardees are
implementing methods to limit these challenges.www.ajpmonline.org
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future scaled-up surveillance of VTE that will aid CDC
in establishing a baseline to monitor and assess effective-
ness of prevention efforts, focus research and prevention
messages, and guide a comprehensive approach to
reducing death and illness due to VTE.
Blood Safety
For many patients with severe thalassemia, therapeutic
blood transfusions are the foundation of care. Therapeu-
tic transfusion also plays a major role in the care of
patients with SCD and Diamond Blackfan anemia.
Consequently, transfusion-related complications may
become a major source of morbidity for these patients.
Fortunately, improved vaccination strategies and advan-
ces in donor testing and deferral have helped reduce the
risk of transfusion-transmitted infection. The risk of
contracting HIV through transfusion has been reduced
to 1 in 2.3 million and the risks for hepatitis B and C have
been reduced to 1 in 277,000 and 1 in 1.9 million,
respectively.29,30 However, noninfectious transfusion
complications continue to be a concern. Iron overload
from repeated transfusions is a severe complication that
can result in early death from organ failure. Alloimmu-
nization, having an antibody to a transfused red blood
cell antigen, can lead to increased incidence of adverse
transfusion reactions and limit or delay the availability of
compatible blood that a patient can receive.
From 2004 to 2012, CDC conducted the Thalassemia
Data and Blood Specimen Collection Project for the early
detection of infections that might be transmitted through
blood transfusion. This system focused on patients
receiving care at seven Thalassemia Treatment Centers
in the U.S. Participants enrolled in the project provided
blood specimens annually that were tested for the
presence of hepatitis A, B, and C virus and HIV. No
transfusion-transmitted infections were detected during
the project, suggesting that, to be timely and useful,
surveillance may need to be broadened to include other
blood disorder patients who receive transfusions as part
of their standard care and to monitor new and emerging
pathogens and noninfectious complications.
In 2012, CDC established the Blood Safety Surveillance
for People with Blood Disorders project to address
current infectious and noninfectious threats for patients
who receive therapeutic red cell transfusions as part of
their care regimen. Two-year cooperative agreements
were awarded to four sites with access to at least 250
patients with nonmalignant blood disorders who receive
at least one therapeutic red cell transfusion per year.
Although CDC has previously partnered with clinical
sites for blood safety surveillance, this is the ﬁrst time thatNovember 2014it has partnered with a state health department as an
awardee for these activities. Each awardee has a unique
approach to obtaining surveillance data, identifying
patients, and obtaining blood specimens. Some look to
utilize existing hospital data systems, and others are
developing novel systems of abstracting patient informa-
tion. Blood specimens are collected upon enrollment to
perform routine laboratory surveillance testing; remain-
ing serum and cells are stored for deep sequencing for
future studies or outbreaks involving blood safety.
This pilot project will help CDC obtain a better
understanding of how best to monitor the rates of and
risks related to transfusion complications and infectious
transmissions as well as increase knowledge of rare blood
types and blood banking practices to better address
alloimmunization. Results will be used to develop and
reﬁne future blood safety surveillance activities with an
ultimate goal of providing information to prevent or limit
complications of chronic transfusion.Conclusions
Nonmalignant blood disorders are diverse in terms of the
affected populations, incidence, prevalence, complica-
tions, and treatment. Different public health surveillance
approaches are called for to effectively assess the burden
and impact of these disorders, as well as to inform and
monitor the effectiveness of prevention strategies. Public
health surveillance is deﬁned as “the ongoing, systematic
collection, analysis, and interpretation of health data,
essential to the planning, implementation and evaluation
of public health practice, closely integrated with the
dissemination of these data to those who need to know
and linked to prevention and control.”31 Although public
health surveillance was once limited to monitoring
infectious diseases, the focus, methods, and uses of
surveillance continue to expand as the need for monitor-
ing the evolving public health challenges facing people
affected by chronic and inherited conditions grows.32,33
CDC is strengthening surveillance activities for blood
disorders by improving and developing new methods
that are tailored to best capture and monitor the
epidemiologic characteristics unique to each disorder.
To be more timely and relevant to the needs of stake-
holders and patients, bleeding disorders and blood safety
surveillance is evolving to address emerging complica-
tions and threats and is broadening its scope to include
previously unmonitored patient groups. In the case of
hemoglobinopathies, multiple data sources (including
clinical, administrative, and laboratory) were used to
develop more comprehensive surveillance that has
resulted in more accurate estimates of hemoglobinopathy
prevalence and burden in the U.S. For VTE, novel
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to inform large-scale surveillance that can more accu-
rately describe and monitor VTE burden in both
inpatient and outpatient settings and provide a baseline
for prevention efforts.
The described CDC blood disorder surveillance activ-
ities will provide much-needed public health data to
assess the magnitude of these conditions and their related
complications, monitor trends and effectiveness of inter-
ventions, and describe patient and provider practices.
These data will inform and provide an evidence base for
public health action to improve the health of patients
affected by and at risk for these disorders.
The ﬁndings and conclusions in this report are those of the
authors and do not necessarily represent the views of CDC.
No ﬁnancial disclosures were reported by the authors of
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